<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163693</url>
  </required_header>
  <id_info>
    <org_study_id>2015-NW-028</org_study_id>
    <nct_id>NCT03163693</nct_id>
  </id_info>
  <brief_title>The Effects of Dexmedetomidine on cTnI and GP-BB in Patients Undergoing OPCABG</brief_title>
  <official_title>The Effects of Dexmedetomidine on Cardiac Troponin I and Glycogen Phosphorylase Isoenzyme BB in Patients Undergoing Off-pump Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the impact of dexmedetomidine on Cardiac Troponin I
      and Glycogen Phosphorylase Isoenzyme BB in patients undergoing off-pump coronary artery
      bypass Grafting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is a highly selective α2-adrenoceptor agonist used as a sedative or adjuvant
      anesthetic drug in clinical settings.From clinical observation, dexmedetomidine has been
      revealed to reduce the incidence of cardiovascular adverse events in patients with heart
      diseases during non‑cardiac surgeries.Therefore, the aim of this sudy is to observe the
      impact of dexmedetomidine on Cardiac Troponin I and Glycogen Phosphorylase Isoenzyme BB in
      patients during cardiac surgeries.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of cardiac troponin I at preoperative, postoperative，and 24 hours after surgery.</measure>
    <time_frame>At preoperative, postoperative，and 24 hours after surgery.</time_frame>
    <description>Blood samples were sampled at preoperative, postoperative，and 24 hours after surgery for the cTnI，which were analyzed by using enzyme linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Glycogen Phosphorylase Isoenzyme BB at preoperative, postoperative，and 24 hours after surgery.</measure>
    <time_frame>At preoperative, postoperative，and 24 hours after surgery.</time_frame>
    <description>Blood samples were sampled at preoperative, postoperative，and 24 hours after surgery for the GP-BB，which were analyzed by using enzyme linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Coronary Artery Bypass, Off-Pump</condition>
  <arm_group>
    <arm_group_label>Group dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>receive dexmedetomidine 0.5 μg/kg</description>
    <arm_group_label>Group dexmedetomidine</arm_group_label>
    <other_name>Dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>receive equal volume of normal saline</description>
    <arm_group_label>Group control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing off - pump coronary artery bypass grafting

          -  ASA physical status III-IV

          -  Aged 40-70 years

          -  NYHA physical status II-III

        Exclusion Criteria:

          -  Bradycardia

          -  Atrioventricular block

          -  Echocardiography suggested:LVEF &lt;40%, LVED&gt;65mm

          -  Allergic to the drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhu Di</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>May 20, 2017</last_update_submitted>
  <last_update_submitted_qc>May 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Cardiac Troponin I</keyword>
  <keyword>Glycogen Phosphorylase Isoenzyme BB</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>safety</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

